Auxergen Files Patent for In-Vitro Cannabinoid Assay
Baltimore, Maryland – March 11, 2024
Auxergen announces its latest product: an in-vitro assay to measure the pharmacokinetics of THC, CBD and like cannabinoids, which promises to revolutionize the field of cannabis research and diagnostics, with application to drug discovery, design, efficacy testing, and a host of therapeutic uses.
The Auxergen cannabinoid biokinetics (CBK) assay enables live cell measurements in real-time, as well as enabling the isolation and study of individual cannabinoid pathways which current commercial assays are unable to support.
Figure 1: Video: Live Cell image of intracellular bioactivity of Cannabinoids in vitro.
Auxergen’s CBK Assay platform enables seven real-time measurements:
• Binding (Kd: nM);
• Uptake (% binding);
• Recycling (% of binding);
• Recycling Kinetics (Half Life; T 1/2);
• Degradation (Half Life; T 1/2);
• Duration (T);
• Degradation (% of uptake)
“We can observe every moment of a cannabinoid’s journey within the cell, from binding to elimination,” said Dr. Ting-Yu Yeh, M.D., inventor of the CBK tool, adding: “It enables unparalleled accuracy in detecting cannabinoids activity living cells and their duration in
the bloodstream.”
Figure 2: Biomarker-tagged receptors reveal intracellular dynamics of cannabinoids.
Additionally, the CBK assay enables us to quantify, for the first time, the “entourage effect.” This is the first scientific proof of presence or absence of the entourage effect and will be of keen interest to cannabis growers and product managers in the CBD/MMJ markets in the US and beyond.
Figure 3: Product Efficacy and The Entourage Effect.
Auxergen’s cannabinoid assay also allows real-time drug response studies at the cellular level, with little background noise, increasing accuracy of results from 70% to 99%, and reducing data readout time from hours to mere seconds.
“This is the new state of the art in drug discovery,” says Greg Contreras, C.E.O., “Mouse models often fail to accurately predict how a drug will work in humans due to fundamental differences in physiology, metabolism, and disease mechanisms between mice and humans”
The Auxergen CBK assay was developed in line with the National Institutes of Health “3Rs” initiative to reduce animal suffering. Mouse models are more expensive and time-consuming to develop than in-vitro models. A mouse study can take months or even years to complete.
Learn more about Auxergen’s innovative work at https://auxergen.com and watch short videos on phages and XylePhage.
###
Auxergen, Inc. is a dedicated team of scientists developing groundbreaking solutions for critical global challenges. Auxergen develops biocontrol agents to reduce the chemical loading of our soils and waterways. Auxergen has is creating bio solutions to combat plant diseases (citrus canker, rice blight, olive quick decline syndrome, etc.) and environmental pollution (heavy metal and PFAS chemical soil clearance technologies) as well as a cannabis biokinetic analysis tool (CBK assay), a bio-antiviral dry fogging technology, and new phage display libraries. Auxergen has also published one dozen high-impact papers in diverse fields such as evolutionary virology, epidemiology, plant pathology and molecular cell biology. We have also filed for three patents, the first one awarded April 2020.
Media Contact:
Michael Feehley
michael@auxergen.com
443.929.9757
